Editor's Note: Our friend Louis Navellier is a regular guest at Mar-a-Lago, President Trump's private residence in Palm Beach Florida. He's also one of America's top tech investors, managing a $1.1 billion portfolio — including $358 million in AI stocks. (He recommended Nvidia to his followers before it soared 44,000%.) In addition, he predicted the Dot-Com crash. He called Google's rise. And now he has a shocking warning about the SpaceX IPO that all Americans deserve to hear. See below for details.

SpaceX went from a $1.75 trillion IPO – the biggest in history...

To a $2.5 trillion valuation just days later.

Elon became the world's first paper trillionaire.

But Elon's dreams of dominating space and AI could soon come crashing down.

And the SpaceX hype train continues, despite some choppy performance in the stock.

But I'm writing to you with an urgent warning.

Do not invest a DIME in SpaceX until you've heard what’s coming.

Because Donald Trump has signed Executive Order (#14363).

Not only could it render SpaceX's AI technology obsolete...

It could trigger a $100 trillion "reset" of the AI markets in America.

And it could "roll back" all the stock's early gains in the process.

How could Trump's executive order end Elon's dreams of AI dominance?

How could it send shares of one obscure AI stock soaring?

And how could you turn this into a massive opportunity, starting now?

Simply click here for my brand-new presentation revealing all the details.

I even reveal the name and ticker of one company poised to profit, for free.

Fair warning: This information is very time sensitive.

I could take it down at any time.

So please don't delay.

Inform yourself now, before you invest a dime in SpaceX.

Louis Navellier
Senior Investment Analyst, InvestorPlace

P.S. I consider this the biggest prediction in my 40-year career. Trump's executive order could send shockwaves throughout the AI economy. As you'll see, he's building a new AI technology 283 trillion times more powerful than Elon's. It may sound crazy. But it's 100% true. And understanding exactly what's coming could save you a lot of money in 2026... while getting you in early on the biggest AI revolution ever.

MarketBeat Week in Review – 06/22 - 06/26

Submitted by MarketBeat Staff. Article Posted: 6/27/2026.

It’s been just two weeks since the SpaceX (NASDAQ: SPCX) IPO, and it’s already starting to feel like back-page news. This week, the market had a long memory for stocks, and that memory backlog is creating a real bottleneck in the artificial intelligence (AI) trade. Adding to volatility in the tech sector was news that OpenAI may postpone its IPO until 2027.

Investors also had to digest the latest inflation reading. The Personal Consumption Expenditures (PCE) index came in hot, with a year-over-year reading showing inflation growth of 4.1%. That’s double the Fed’s preferred target. The silver lining? The reading was as expected.

The $15 Gold Fund That Pays Up to $1,152/Month (Ad)

Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.

Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.

Discover the gold income fund before the next payout date

Next week will be another short trading week. Markets will be closed on Friday, July 3, in observance of the Fourth of July holiday in the United States. The MarketBeat team of analysts will be getting you ready for the current volatility and helping you position for the upcoming earnings season. Here are some of our most popular articles from this week.

Articles by Thomas Hughes

Is the sell-off in Oracle (NYSE: ORCL) overdone? That’s the question Thomas Hughes addressed head-on. Hughes made the case that what started as an understandable but overblown concern over debt has now become a case of mispricing more than a warning.

Investors may be wondering how to position themselves in energy stocks with oil prices moving lower. Hughes recommended three oil refiners that are positioned to benefit from short-term market dynamics that will keep supply tight.

Oil prices are coming down, but it will take time for inflation to follow suit. That’s likely to keep pressure on the retail sector, which is why Hughes focused on three inflation-resistant stocks that stand out when inflation is running hot.

Articles by Sam Quirke

It was another week of one step forward and two steps back for Amazon.com Inc. (NASDAQ: AMZN). Sam Quirke highlighted a potential complaint being brought by the Federal Trade Commission (FTC). However, Quirke reminded long-term investors that Amazon has a history of absorbing regulatory blows to the benefit of shareholders.

Tesla Inc. (NASDAQ: TSLA) is facing regulatory scrutiny of a different kind. In this case, the company faces a probe from the National Highway Traffic Safety Administration (NHTSA) after a crash involving one of its Model 3 cars, which raised fresh concerns about full self-driving (FSD).

Quirke also wrote about Applied Materials (NASDAQ: AMAT) and concerns that the stock is starting to look bubblicious. Read why the long-term story is bullish, but that doesn’t mean AMAT may not face short-term pressure.

Articles by Chris Markoch

This was the last week for investors to buy CrowdStrike Holdings Inc. (NASDAQ: CRWD) before its 4-for-1 stock split. Chris Markoch reminded investors that a stock split is never the right reason to buy a stock, but in the case of CRWD, it’s coming as the company’s fundamentals point to a higher price regardless of its current price.

Microsoft (NASDAQ: MSFT) continues to be one of the market’s weakest performers. But Markoch pointed out that while the company remains a tech stalwart, its boring business includes a beautiful balance sheet.

Higher-for-longer interest rates are increasing interest in dividend stocks that offer yields above inflation and the 10-year rate. This week, Markoch highlighted three dividend stocks with a yield over 4% that are priced under $30, which can make them appealing for investors looking for an anchor for their portfolio.

Articles by Ryan Hasson

The SpaceX IPO has triggered a wave of leveraged ETF launches within days of its listing. This week, Ryan Hasson helped investors understand the structure and risk of these funds and highlighted two of the biggest names: one long and one short.

The biotechnology sector has been hinting at a fundamental breakout for some time. This week, Hasson explained why the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) may be the most efficient way for many investors to capture gains in this trade.

One of the largest beneficiaries of the AI infrastructure trade has been companies responsible for delivering the power data centers need. Hasson highlighted five stocks that will power the AI power crisis.

Articles by Leo Miller

Investors are drawn to insider buying and selling, which can best be summarized as: it doesn’t matter unless it does. This week, Leo Miller pointed investors to two stocks with heavy insider selling that could signal a short-term top for the respective stocks. He also highlighted one company where insiders are buying shares on weakness.

Miller also highlighted three big names in the consumer discretionary sector that have made significant increases to their share buyback programs. The devil is in the details, and investors should be aware of the circumstances surrounding each of these increases.

Dividend investors understand that the best dividends grow over time. This week, Miller put a spotlight on three companies that recently raised their dividends. One of those names also offers investors a high yield of over 10%.

Articles by Nathan Reif

After a disappointing earnings report, D-Wave Quantum (NYSE: QBTS) needed a win. Nathan Reiff explained why the company’s announcement of an upcoming gate-model quantum computing simulator may not be a game-changer, but it could be the lifeline the company needed.

Many defense and space stocks have been sliding after the SpaceX IPO. But Reiff pointed investors to two names with significant backlogs that could make this pullback a buying opportunity.

A major story this week was the plunge in South Korea’s Kospi index. That may have some investors concerned about investing in the country. But Reiff highlighted three South Korea ETFs that offer more runway despite the significant gains already made in 2026.

Articles by Dan Schmidt

Investors have been encouraged to look outside the United States for market-beating returns. One example came from European banks that had a strong year in 2025. That has some calling a bubble, but Dan Schmidt explained why three European banks continue to be undervalued compared to their U.S. peers.

The trend of Bitcoin miners becoming data center landlords is a key story in 2026. However, Schmidt highlighted three Bitcoin miners that have posted strong gains but may be due for a pullback.

Schmidt also pointed out the market-beating growth of The Cheesecake Factory (NASDAQ: CAKE). This is less about the company’s flagship namesake brand and more about its strategic expansion. The question is whether the 50% year-to-date gain has room to run.

Articles by Jeffrey Neal Johnson

Micron Technology (NASDAQ: MU) delivered one of the most important earnings reports this season. However, prior to the report, the stock sold off more than 8% in sympathy with an implosion in South Korea’s Kospi Index. Jeffrey Neal Johnson explained why nimble investors used the sell-off as a setup for the bullish rally.

After soaring following its IPO, SpaceX is confronting the market reality of gravity. Johnson provides investors with context that could mean the sell-off is structural, not just a profit-taking exercise.

The hottest part of the AI infrastructure trade is about keeping things cool. Johnson wrote about three liquid cooling stocks as futuristic technology becomes increasingly important for keeping the modern internet online.

Articles by Jennifer Ryan Woods

Shares of Sweetgreen Inc. NYSE: SG have surged 60% over the past three months. Jennifer Ryan Woods explained why the company's efforts to revive the business suggest that what started as a relief rally may have more room to run.

It’s been a rough first half for Domino’s Pizza (NASDAQ: DPZ), and shares are near a 52-week low after the company announced a change in the C-suite. However, Woods noted that analysts still forecast strong upside, which could show up in the stock if the company can deliver on earnings.

Articles by Peter Frank

Cruise lines have delivered strong results this earnings season. However, Peter Frank highlighted two different risks for two of the biggest names. In the case of Royal Caribbean (NYSE: RCL), the company posted a double-digit revenue increase with further growth projected. However, investors have to ask if that growth is already priced in.

For Carnival Corp. (NYSE: CCL), the strong report comes with concerns about the company’s future guidance, which includes higher fuel costs and a mixed picture about confidence in its core customer base.

Like many off-price retailers, Burlington Stores (NYSE: BURL) is having a strong year. However, Frank pointed out that the growth has created a potential valuation concern, meaning the company needs flawless execution to move higher.

3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend

Submitted by Nathan Reiff. Article Posted: 6/20/2026.

The GLP-1 revolution is quietly continuing, even as investor attention has shifted to more timely topics. One of the best ways to gain exposure to the fast-growing weight loss drug space is through makers like Novo Nordisk (NYSE: NVO) or Eli Lilly (NYSE: LLY), the leading companies behind products such as Ozempic and Zepbound.

There are, of course, less direct ways for investors to benefit from the GLP-1 rush as well. The prospect of the market tripling in size over the coming years has enticed a host of other drug developers to pursue their own offerings, and a number of up-and-coming pharma firms may be worth watching — or investors can look at dedicated exchange-traded funds (ETFs) like the Roundhill GLP-1 & Weight Loss ETF (NASDAQ: OZEM) for a broader view.

They gave the crew 64 days. It took 16. (Ad)

A drilling crew in rural Utah was handed a 64-day timeline to bore through nearly three miles of solid granite. They finished in 16 days - twelve years ahead of the DOE's own performance projections.

Drilling costs were cut in half in 18 months. Google signed a 15-year contract. Bill Gates reversed his position and committed $100 million. When Congress rewrote energy tax credits, this was the one source that kept them through 2033. The company behind it has been operating for sixty years.

See the company that just rewrote the DOE's timeline

But the impact of GLP-1 agonists is extending beyond the pharma space, and the companies below could benefit from this trend despite not being directly involved.

GLP-1 Telehealth Business Positioned to Thrive

Teladoc Health (NYSE: TDOC) operates a telehealth platform that provides patients with virtual care services related to obesity management and metabolic health, among other offerings.

These areas of Teladoc's business, along with GLP-1 prescription initiation, are growing particularly rapidly. The company makes it as easy as possible for qualified patients to access GLP-1 treatment, which can be a game-changer for those without convenient access to in-person specialists.

This has had a real impact on Teladoc's results. In Q1 2026, for instance, the firm beat revenue expectations by about $3 million at $614 million, and adjusted EBITDA of $58 million also came in ahead of guidance. Visit-based care is being enhanced by AI-enabled 24/7 offerings, which should likely serve as a sales and margin driver throughout the rest of this year at least.

At the same time, Teladoc is working to right its balance sheet by initiating a multi-step debt reduction process and planning to limit stock-based compensation to $55 million or less in the coming year. The firm is also building financial strength with a cash reserve that reached $751 million at the end of the first quarter.

This is a welcome change for investors after several consecutive quarters of shaky financial health, as indicated by a TradeSmith health indicator in the red zone.

GLP-1 Customers Buying New Wardrobes Might Fuel This Retailer's Growth

Discount retailer Ollie's Bargain Outlet (NASDAQ: OLLI) may seem like an unlikely beneficiary of GLP-1 drugs, but this and similar clothing stores could play an increasingly important role for patients losing weight and needing to buy new clothes.

Ollie's is among the most aggressive discount clothing retailers in terms of pricing and could be well-positioned to gain business from GLP-1 patients seeking to replace a large volume of clothes quickly.

For Q1 2026, Ollie's reported strong results overall, including sales growth of 14% year over year (YOY) and comparable-store sales improvement of 1.7% over the same period.

Adjusted earnings per share (EPS) increased by 21% YOY as well, despite headwinds including inflation and higher fuel prices.

Ollie's is also expanding rapidly, with 27 new stores opening in the first quarter of the year and a planned 75 new openings in total this year.

OLLI stock is a Moderate Buy across Wall Street, based on 14 Buy ratings and three Holds. Shares have fallen by almost 30% year to date (YTD) but still have about 60% upside potential based on analyst price targets.

Glucose Monitoring Devices Could Surge in Popularity

Although not a pharma company, health care peer DexCom (NASDAQ: DXCM) is a medical device firm that could benefit from the GLP-1 trend because of its continuous glucose monitoring (CGM) tools. CGMs are vital for GLP-1 patients with Type 2 diabetes, making these products a useful companion to GLP-1 treatment in some cases.

Care providers may increasingly view CGMs and GLP-1s as a combined solution for patients with diabetes. CGMs have long been associated with insulin treatments, but the rapid expansion of GLP-1s beyond the population of patients with diabetes has the potential to open up monitoring needs for those interested in tracking glucose trends even if they are not also using insulin. DexCom has responded by launching over-the-counter products for a wider patient population.

Overall, more people becoming aware of metabolic health and interested in monitoring their own glucose levels could mean a surge in business for DexCom. This may contribute to DexCom's strong popularity among analysts: the stock has 22 Buy ratings compared to three Holds and one Sell, alongside 17% predicted upside potential.